Recite me link

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products:
a. Aranesp & Aranesp SureClick (darbepoetin alpha)
b. Eprex (epoetin alfa)
c. NeoRecormon (epoetin beta)
d. Retacrit (epoetin zeta)
e. Mircera (methoxy polyethylene glycol-epoetin beta)
f. Ferinject (ferric carboxymaltose injection/infusion)
g. Diafer (ferric derisomaltose injection)
h. Monofer (ferric derisomaltose injection)
i. Cosmofer (iron dextran injection)
j. Venofer (iron sucrose injection)
Q2. In the past 6 months could you please state the number of patients treated for the following conditions:
a. Chronic kidney disease (ICD10 code – N.18)
b. Chronic kidney disease – Stages 4 & 5 (ICD10 codes – N.18.3 & N.18.4 & N.18.5)
c. Acquired cystic kidney disease (ICD10 code N28.1)
d. Chronic kidney disease – new patients (excluding previously treated patients)
e. Acquired cystic kidney disease – new patients (excluding previously treated patients)
Q3. Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:
a. Aranesp & Aranesp SureClick (darbepoetin alpha)
b. Eprex (epoetin alfa)
c. NeoRecormon (epoetin beta)
d. Retacrit (epoetin zeta)
e. Mircera (methoxy polyethylene glycol-epoetin beta)
f. Ferinject (ferric carboxymaltose injection/infusion)
g. Diafer (ferric derisomaltose injection)
h. Monofer (ferric derisomaltose injection)
i. Cosmofer (iron dextran injection)
j. Venofer (iron sucrose injection)

Download response Chronic Kidney Disease. 081021.docx